A phase 1 study of the pan‐bromodomain and extraterminal inhibitor mivebresib (ABBV‐075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia

BACKGROUND: Acute myeloid leukemia (AML) is a heterogenous malignancy driven by genetic and epigenetic factors. Inhibition of bromodomain and extraterminal (BET) proteins, epigenetic readers that play pivotal roles in the regulation of genes relevant to cancer pathogenesis, constitutes a novel AML t...

Descripción completa

Detalles Bibliográficos
Autores principales: Borthakur, Gautam, Odenike, Olatoyosi, Aldoss, Ibrahim, Rizzieri, David A., Prebet, Thomas, Chen, Chris, Popovic, Relja, Modi, Dimple A., Joshi, Rujuta H., Wolff, Johannes E., Jonas, Brian A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360206/
https://www.ncbi.nlm.nih.gov/pubmed/33934351
http://dx.doi.org/10.1002/cncr.33590

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360206/
https://www.ncbi.nlm.nih.gov/pubmed/33934351
http://dx.doi.org/10.1002/cncr.33590

Ejemplares similares